The effect of ivermectin on the viral load and culture viability in early treatment of nonhospitalized patients with mild COVID-19 – a double-blind, randomized placebo-controlled trial

Ivermectin is a Food and Drug Administration-approved broad-spectrum antiparasitic agent, initially approved for humans in 1987 to treat onchocerciasis and awarded the Nobel Prize of Medicine to the discoverers in 2015. Its primary use is treating infections caused by roundworm parasites. However, over the years, the spectrum was extended to include a variety of parasitic skin infections, such as scabies (Laing et  al., 2017).
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Source Type: research